Status: Not yet recruiting
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
The purpose of this study is to evaluate efficacy and of safety QL0911 in the treatment of thrombocytopenia in pediatric patients with previously treated chronic ITP.
Participants needed: 60
Trial details
Phase: Phase 3Age: 1-17Biological sex: AllType: InterventionalSponsor: Qilu Pharmaceutical Co., Ltd.Updated: Mar 6, 2026
Eligibility criteria
Age ≥ 1 years old and < 18 years old. [+5]
Had a history of bone marrow stem cell abnormalities or myelodysplastic syndrome... [+8]